Treatment protocol determines the efficacy of clindamycin in acute murine toxoplasmosis
Samo za registrovane korisnike
1999
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
To determine the contribution to the efficacy of clindamycin in acute murine toxoplasmosis of treatment protocol variables, groups of Swiss Webster mice inoculated intraperitoneally with 10(2) RH strain Toxoplasma gondii tachyzoites were treated with peroral clindamycin at 25, 50 and 400 mg/kgBM per day for 1, 2 and 3 weeks. While the lowest drug dose applied for a single week prolonged survival time as compared to untreated animals, not even the highest dose applied for 1 or 2 weeks completely prevented mortality. Conversely, 100% protection was achieved with 3-week treatment courses at both 50 and 400 mg/kg per day. While both survival rates and survival times increased in parallel with the drug dose and treatment duration, the latter was shown to be critical to the outcome, suggesting the use of clindamycin as an antitoxoplasmic agent should be as a prolonged course.
Ključne reči:
Toxoplasma gondii / murine model / clindamycin / treatment protocolIzvor:
International Journal of Antimicrobial Agents, 1999, 11, 2, 145-149Izdavač:
- Elsevier, Amsterdam
DOI: 10.1016/S0924-8579(98)00064-8
ISSN: 0924-8579
PubMed: 10221418
WoS: 000079708800009
Scopus: 2-s2.0-0345291186
Institucija/grupa
Institut za medicinska istraživanjaTY - JOUR AU - Nikolić, T. AU - Đurković-Đaković, Olgica AU - Bobić, Branko AU - Nikolić, A. AU - Babić, D PY - 1999 UR - http://rimi.imi.bg.ac.rs/handle/123456789/51 AB - To determine the contribution to the efficacy of clindamycin in acute murine toxoplasmosis of treatment protocol variables, groups of Swiss Webster mice inoculated intraperitoneally with 10(2) RH strain Toxoplasma gondii tachyzoites were treated with peroral clindamycin at 25, 50 and 400 mg/kgBM per day for 1, 2 and 3 weeks. While the lowest drug dose applied for a single week prolonged survival time as compared to untreated animals, not even the highest dose applied for 1 or 2 weeks completely prevented mortality. Conversely, 100% protection was achieved with 3-week treatment courses at both 50 and 400 mg/kg per day. While both survival rates and survival times increased in parallel with the drug dose and treatment duration, the latter was shown to be critical to the outcome, suggesting the use of clindamycin as an antitoxoplasmic agent should be as a prolonged course. PB - Elsevier, Amsterdam T2 - International Journal of Antimicrobial Agents T1 - Treatment protocol determines the efficacy of clindamycin in acute murine toxoplasmosis EP - 149 IS - 2 SP - 145 VL - 11 DO - 10.1016/S0924-8579(98)00064-8 ER -
@article{ author = "Nikolić, T. and Đurković-Đaković, Olgica and Bobić, Branko and Nikolić, A. and Babić, D", year = "1999", abstract = "To determine the contribution to the efficacy of clindamycin in acute murine toxoplasmosis of treatment protocol variables, groups of Swiss Webster mice inoculated intraperitoneally with 10(2) RH strain Toxoplasma gondii tachyzoites were treated with peroral clindamycin at 25, 50 and 400 mg/kgBM per day for 1, 2 and 3 weeks. While the lowest drug dose applied for a single week prolonged survival time as compared to untreated animals, not even the highest dose applied for 1 or 2 weeks completely prevented mortality. Conversely, 100% protection was achieved with 3-week treatment courses at both 50 and 400 mg/kg per day. While both survival rates and survival times increased in parallel with the drug dose and treatment duration, the latter was shown to be critical to the outcome, suggesting the use of clindamycin as an antitoxoplasmic agent should be as a prolonged course.", publisher = "Elsevier, Amsterdam", journal = "International Journal of Antimicrobial Agents", title = "Treatment protocol determines the efficacy of clindamycin in acute murine toxoplasmosis", pages = "149-145", number = "2", volume = "11", doi = "10.1016/S0924-8579(98)00064-8" }
Nikolić, T., Đurković-Đaković, O., Bobić, B., Nikolić, A.,& Babić, D.. (1999). Treatment protocol determines the efficacy of clindamycin in acute murine toxoplasmosis. in International Journal of Antimicrobial Agents Elsevier, Amsterdam., 11(2), 145-149. https://doi.org/10.1016/S0924-8579(98)00064-8
Nikolić T, Đurković-Đaković O, Bobić B, Nikolić A, Babić D. Treatment protocol determines the efficacy of clindamycin in acute murine toxoplasmosis. in International Journal of Antimicrobial Agents. 1999;11(2):145-149. doi:10.1016/S0924-8579(98)00064-8 .
Nikolić, T., Đurković-Đaković, Olgica, Bobić, Branko, Nikolić, A., Babić, D, "Treatment protocol determines the efficacy of clindamycin in acute murine toxoplasmosis" in International Journal of Antimicrobial Agents, 11, no. 2 (1999):145-149, https://doi.org/10.1016/S0924-8579(98)00064-8 . .